Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 549

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 549
---
 said firm as experts in auditing and accounting. The financial statements of NLS Pharmaceutics Ltd. included in this proxy statement/prospectus for the year ended December31, 2024 have been so included in reliance on the report (which contains an explanatory paragraph relating to NLS’s ability to continue as a going concern as described in Note 1 to the financial statements) of Marcum LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The financial statements of Kadimastem Ltd. as of December31, 2024 and for each of the three years in the period ended December 31, 2024 included in this proxy statement/prospectus, have been audited by Kost Forer Gabbay & Kasierer, a Member of EY Global, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about Kadimastem Ltd.’s ability to continue as a going concern as described in Note 1B to the financial statements) and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. 313 DELIVERY OF DOCUMENTS TO SHAREHOLDERS Pursuant to the rules of the SEC, NLS and services that it employs to deliver communications to its shareholders are permitted to deliver to two or more shareholders sharing the same address a single copy of each of NLS’s annual report to shareholders and NLS’s proxy statement. Upon written or oral request, NLS will deliver a separate copy of the annual report to any shareholder and/or proxy statement to any shareholder at a shared address to which a single copy of each document was delivered and who wishes to receive separate copies of such documents. Shareholders receiving multiple copies of such documents may request that NLS deliver single copies of such documents in the future. Shareholders may notify NLS of their requests by calling or writing NLS at its principal executive offices at NLS Pharmaceutics Ltd., The Circle6, 8058 Zurich, Switzerland and its telephone number +41.44.512.2150. Following the Merger, such requests should be made by calling or writing to NLS Pharmaceutics Ltd., The Circle6, 8058 Zurich, Switzerland and its telephone number +41.44.512.2150. SOLICITATION OF PROXIES NLS will bear the cost of